Critical ill in intensive care units. Illness, unspecified
Conditions
Interventions
Intervention 1: intervention groups:25 patients with critical ill who receive commercially available l-carnitine supplements with a dose of 3000 Mg are given to the patients by nurses and supervised b
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age of 18 years older Conscious informed consent Critical ill patients Patients with recently diagnosed critical ill
Exclusion criteria
Exclusion criteria: Dissatisfaction with the patient or family of the patient to continue the intervention Patients with liver and kidney failure Patients who have cancer and are taking chemotherapy and cisplatin Patients taking phenobarbital and phenytoin anti-inflammatory drugs Patients taking pivolic acid, valproic acid, and fosfamide drugs Patients undergoing dialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-6. Timepoint: The first of study,the end of study 21th day. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anthropometric indices. Timepoint: Before and after study. Method of measurement: ELISA.;Mid-arm circumference (MAC). Timepoint: Before and after study. Method of measurement: . The height of each patient is measured in the lying state or through the length of the ulna and the circumference of the middle of the non-dominant hand arm with a non-transient strip meter with an accuracy of 5.5 cm.;Severity of illness. Timepoint: Before and after study. Method of measurement: Based on APACHEII questionnaire.;Examining organ dysfunction. Timepoint: Before and after study. Method of measurement: Based on sequential organ failure assessment (SOFA) questionnaire.;NUTRIC score questionnaire. Timepoint: Before and after study. Method of measurement: Based on Nutrition Risk in Critically ill (NUTRIC) questionnaire.;Acute Phosphorus Reactive Protein Level (CRP) Level - Inflammatory Cytokines Levels Including IL-10, IL-8 , IL-6, IL-4, IL-2, IL-1 ß, IFN-?, TNF-a. Timepoint: Before and after study. Method of measurement: ELISA.;Procalcitonin Factor. Timepoint: before and after study. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbdolreza Norozi
Mashhad University of Medical Sciences
Outcome results
None listed